No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Sector
Medical - Devices
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.
www.medtronic.comNo one on the platform currently holds 2M6.DE.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-06-30 | 636,341 | $50.1M |
No one on the platform has traded 2M6.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.8% | 6.5% | 6.5% | — | — | — |
| Rev. Growth % | 8.4% | 3.8% | ||||
| Profit Margin % | 13.2% | 13.3% | 13.4% | |||
| Free Cash Flow Margin % | 14.9% | 16.0% | 16.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $38.8B | +7.4% | $5.94 | $5.55–$6.08 | — | 1 |
| 2028 | $40.1B | +3.2% | $6.35 | $5.94–$6.50 | — | 1 |
| 2029 | $41.9B | +4.6% | $6.87 | $6.42–$7.03 | — | 1 |
| 2030 | $44.5B | +6.2% | $7.45 | $6.97–$7.63 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-09-01 | $1.21 | $1.26 | +4.1% |
| 2026-06-03 | $1.31 | $1.32 | +0.8% |
| 2026-02-17 | $1.13 | $1.15 | +1.8% |
| 2025-11-18 | $1.14 | $1.18 | +3.5% |
| 2025-08-19 | $1.08 | $1.10 | +1.9% |
| 2025-05-21 | $1.40 | $1.43 | +2.1% |
| 2025-02-18 | $1.31 | $1.34 | +2.3% |
| 2024-11-19 | $1.15 |
| $1.16 |
| +0.9% |
| -1.13% |
| $154.9B |
| — |
| PFE.DEPfizer Inc. | $23.94 | -0.48% | $136.4B | — |
| PFE.FPfizer Inc. | $23.64 | -1.73% | $134.7B | — |
Source: Financial Modeling Prep · peers by sector/industry